IP Library Patent Application 12786280
Patent Application
App. No. 12/786,280

HALOGENATED RHODAMINE DERIVATIVES AND APPLICATIONS THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/786,280
Abstract

Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodmaine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. Examples of rhodamine compounds include 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4′, 5′-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt of 2,7-dibromo-4′-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide.

Claims (24)

1 . A method for treating a tissue sample from a patient, comprising the steps of:

harvesting the tissue sample from the patient, wherein the tissue sample is infected with bacteria;

providing a rhodamine compound selected from the group consisting of 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4′,5′-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt of 2,7-dibromo-4′-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide;

mixing the rhodamine compound and the tissue sample to form a mixture,

exposing the mixture to radiant energy to inhibit or kill the bacteria; and

transplanting the exposed mixture into the patient.

2 . The method of claim 1 , wherein the bacteria is gram positive.

3 . The method of claim 1 , wherein the bacteria is gram negative.

4 . The method of claim 1 , wherein the bacteria is Staphylococcus epidermitis.

5 . The method of claim 1 , wherein the bacteria is at least one of Escherichia coli 0157:H7 or Salmonella thyphimurium , and wherein the rhodamine compound is 4,5-dibromo rhodamine 110 2-(2-methoxy ethoxy)ethyl ester.

6 . The method of claim 1 , wherein the bacteria is Salmonella thyphimurium LT2, and wherein the rhodamine compound is the acetate salt of 2,7-dibromorhodamine B hexyl ester.

7 . The method of claim 1 , wherein the bacteria is Escherichia coli 0157:H7, and wherein the rhodamine compound is 4,5-dibromorhodamine 6G hydrobromide

8 . The method of claim 1 , wherein the bacteria is Escherichia coli 0157TH7, and wherein the compound is rhodamine B 3-bromopropyl ester.

9 . The method of claim 1 , wherein the bacteria is selected from the group consisting of Escherichia coli 0157TH7, Salmonella thyphimurium LT2, and Pseudomonas aeruginosa , and wherein the rhodamine compound is 4,5-dibromorhodamine methyl ester.

10 . The method of claim 1 , wherein the mixture is exposed to a wavelength of 514 nm.

11 . The method of claim 1 , wherein the tissue sample is blood.

12 . The method of claim 1 , wherein the tissue sample is bone marrow.

13 . The method of claim 1 , wherein the mixture is exposed to radiant energy for 180 minutes.

14 . The method of claim 1 , further comprising the steps of

centrifuging the mixture:

resuspending the centrifuged mixture; and

incubating the resuspended centrifuged mixture.

15 . The method of claim 14 , wherein the resuspended centrifuged mixture is incubated for 90 minutes.

16 . The method of claim 14 , wherein the resuspended centrifuged mixture is incubated before exposing the mixture to radiant energy.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2010
From: HABI, ABDELKRIM; GRAVEL, DENIS; VILLENEUVE, LUC; FORTE, JEAN-PIERRE; SU, HONGSHENG; VAILLANCOURT, MARC
To: THERATECHNOLOGIES, INC.
Reel/Frame 024957/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2010
From: THERATECHNOLOGIES INC.
To: CELMED BIOSCIENCES INC.
Reel/Frame 024957/0373 →
CHANGE OF NAME Recorded Sep 8, 2010
From: CELMED BIOSCIENCES INC.
To: KIADIS PHARMA CANADA INC.
Reel/Frame 024957/0483 →